Single-dose pharmacokinetics of temocapril and temocapril diacid in subjects with varying degrees of renal impairment (original) (raw)

Abstract

Objective: The aim of this study was to determine the influence of renal impairment on the single-dose pharmacokinetics of temocapril and its pharmacologically active metabolite, temocapril diacid.

Methods: A single oral dose of 20 mg temocapril hydrochloride was given after an overnight fast to eight healthy (control) subjects (group A, _n_=8) with a mean baseline creatinine clearance (CLCR) of 115.2 ml · min−1 and to three groups of patients with decreased renal function (mean CLCR 56.9 ml in group B, _n_=8, 30.0 ml · min−1 in group C, _n_=8 and 15.4 ml · min−1 in group D, _n_=5).

Results: The mean peak concentration and median time to peak concentration for both temocapril and its diacid metabolite as well as the mean area under the curve (AUC0∞) for temocapril did not differ significantly between groups. The mean AUC0∞ for temocapril diacid increased only two- to threefold from group A to D. The mean terminal elimination half-life (t½) for temocapril diacid was prolonged in subjects with impaired renal function. However, prolongation of mean t½ and increase in AUC0−∞ did not parallel the decrease of mean renal clearance for temocapril diacid.

Conclusion: The results suggest the existence of an alternative pathway in addition to the renal excretion of temocapril, e.g. via the bile. This pathway substantially contributes to the elimination of the active metabolite, temocapril diacid, in patients with decreased renal function. Nonetheless, to avoid any risks, the dose of temocapril hydrochloride in patients with moderate to severe renal impairment should be reduced.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

Author information

Authors and Affiliations

  1. Sankyo Europe GmbH, Immermannstrasse 45, D-40210 Duesseldorf, Germany Tel. +49 211 367 88-52; Fax +49 211 362 799, , , , , , DE
    B. Sierakowski, K. Püchler & K. Renneisen
  2. Imform GmbH, D-02826 Goerlitz, Germany, , , , , , DE
    P. U. Witte
  3. Institute of Clinical Pharmacology, University Clinic Charité, Humboldt University, D-10098 Berlin, Germany, , , , , , DE
    I. Roots

Authors

  1. B. Sierakowski
    You can also search for this author inPubMed Google Scholar
  2. K. Püchler
    You can also search for this author inPubMed Google Scholar
  3. P. U. Witte
    You can also search for this author inPubMed Google Scholar
  4. K. Renneisen
    You can also search for this author inPubMed Google Scholar
  5. I. Roots
    You can also search for this author inPubMed Google Scholar

Additional information

Received: 16 April 1997 / Accepted in revised form: 24 July 1997

Rights and permissions

About this article

Cite this article

Sierakowski, B., Püchler, K., Witte, P. et al. Single-dose pharmacokinetics of temocapril and temocapril diacid in subjects with varying degrees of renal impairment.E J Clin Pharmacol 53, 215–220 (1997). https://doi.org/10.1007/s002280050365

Download citation